Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Other Non Operating Income (2020 - 2023)

Historic Other Non Operating Income for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to $126.0 million.

  • ADC Therapeutics' Other Non Operating Income rose 43942.14% to $126.0 million in Q3 2023 from the same period last year, while for Sep 2023 it was $126.0 million, marking a year-over-year increase of 126784.85%. This contributed to the annual value of -$604.0 million for FY2022, which is 32648638648.65% down from last year.
  • ADC Therapeutics' Other Non Operating Income amounted to $126.0 million in Q3 2023, which was up 43942.14% from -$1.5 billion recorded in Q2 2023.
  • In the past 5 years, ADC Therapeutics' Other Non Operating Income ranged from a high of $126.0 million in Q3 2023 and a low of -$1.5 billion during Q2 2023
  • Over the past 5 years, ADC Therapeutics' median Other Non Operating Income value was $14.0 (recorded in 2019), while the average stood at -$84.4 million.
  • In the last 5 years, ADC Therapeutics' Other Non Operating Income soared by 367277759.56% in 2022 and then crashed by 1141650.49% in 2023.
  • Over the past 5 years, ADC Therapeutics' Other Non Operating Income (Quarter) stood at $222.0 in 2019, then skyrocketed by 65215.32% to $145000.0 in 2020, then tumbled by 89.01% to $15929.0 in 2021, then tumbled by 108.0% to -$1275.0 in 2022, then skyrocketed by 9882452.94% to $126.0 million in 2023.
  • Its Other Non Operating Income was $126.0 million in Q3 2023, compared to -$1.5 billion in Q2 2023 and $18.0 in Q1 2023.